Advantages of organ-sparing treatment approaches in metastatic kidney cancer.
Cytoreductive nephrectomy
Cytoreductive partial nephrectomy
Metastatic renal cell carcinoma
Organ sparing management
Remaining functioning parenchyma volume
Targeted therapy
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
09
05
2022
accepted:
15
07
2022
medline:
5
7
2023
pubmed:
24
7
2022
entrez:
23
7
2022
Statut:
ppublish
Résumé
This study analyzed oncological outcomes of patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with cytoreductive partial nephrectomy or nephrectomy. This prospective non-randomized cohort study included 109 patients with metastatic ccRCC who underwent surgical treatment between 2011 and 2020. Patients were stratified into cytoreductive partial nephrectomy or nephrectomy groups. Survival curves were estimated, and Cox-regression analysis was performed to identify factors affecting potential lethality. The groups differed significantly in terms of T stage and International metastatic RCC database consortium (IMDC) risk groups, but not international society of urological pathology (ISUP) grading. The average blood loss volume was higher in the partial nephrectomy group. In contrast, the duration of post-operative stay, complication rate; and 30-day hospital readmission rate were similar between two groups. There was a significant difference in overall survival in favor of the partial nephrectomy group, who had better 7-year survival rates. Standardization based on the clinical complexity of the patients showed that cytoreductive partial nephrectomy was associated with a lower risk of death compared to nephrectomy. Partial nephrectomy is a safe method of choice in patients with metastatic ccRCC. Kidney preservation in a metastatic setting can play a role in reducing potential adverse systemic therapy events and in decreasing the risk for concomitant pathology deterioration.
Identifiants
pubmed: 35870012
doi: 10.1007/s00432-022-04216-6
pii: 10.1007/s00432-022-04216-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3131-3137Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ (2014) Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res 34:2405–2411
pubmed: 24778051
Barbastefano J, Garcia JA, Elson P et al (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int 106:1266–1269. https://doi.org/10.1111/j.1464-410X.2010.09323.x
doi: 10.1111/j.1464-410X.2010.09323.x
pubmed: 20346042
Barlow LJ, Korets R, Laudano M, Benson M, McKiernan J (2010) Predicting renal functional outcomes after surgery for renal cortical tumours: A multifactorial analysis. BJU Int 106:489–492. https://doi.org/10.1111/j.1464-410X.2009.09147.x
doi: 10.1111/j.1464-410X.2009.09147.x
pubmed: 20039869
Bex A, Mulders P, Jewett M et al (2019) Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME randomized clinical trial. JAMA Oncol 5:164–170. https://doi.org/10.1001/jamaoncol.2018.5543
doi: 10.1001/jamaoncol.2018.5543
pubmed: 30543350
Bhindi B, Abel EJ, Albiges L et al (2019) Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol 75:111–128. https://doi.org/10.1016/j.eururo.2018.09.016
doi: 10.1016/j.eururo.2018.09.016
pubmed: 30467042
Buchler T, Bortlicek Z, Poprach A et al (2016) Outcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysis. Eur Urol 70:469–475. https://doi.org/10.1016/j.eururo.2015.12.031
doi: 10.1016/j.eururo.2015.12.031
pubmed: 26746623
Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829–841. https://doi.org/10.1056/NEJMoa2026982
doi: 10.1056/NEJMoa2026982
pubmed: 33657295
pmcid: 8436591
de Bruijn R, Wimalasingham A, Szabados B et al (2020) Deferred cytoreductive nephrectomy following presurgical vascular endothelial growth factor receptor-targeted therapy in patients with primary metastatic clear cell renal cell carcinoma: a pooled analysis of prospective trial data. Eur Urol Oncol 3:168–173. https://doi.org/10.1016/j.euo.2019.12.004
doi: 10.1016/j.euo.2019.12.004
pubmed: 31956080
de Groot S, Redekop WK, Sleijfer S et al (2016) Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: Results from a population-based registry. Urology 95:121–127. https://doi.org/10.1016/j.urology.2016.04.042
doi: 10.1016/j.urology.2016.04.042
pubmed: 27179773
Estrada CC, Maldonado A, Mallipattu SK (2019) Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol 30:187–200. https://doi.org/10.1681/ASN.2018080853
doi: 10.1681/ASN.2018080853
pubmed: 30642877
pmcid: 6362621
Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076. https://doi.org/10.1097/01.ju.0000110610.61545.ae
doi: 10.1097/01.ju.0000110610.61545.ae
pubmed: 14767273
Gershman B, Thompson RH, Boorjian SA et al (2018) Radical versus partial nephrectomy for cT1 renal cell carcinoma. Eur Urol 74:825–832. https://doi.org/10.1016/j.eururo.2018.08.028
doi: 10.1016/j.eururo.2018.08.028
pubmed: 30262341
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305. https://doi.org/10.1056/NEJMoa041031
doi: 10.1056/NEJMoa041031
pubmed: 15385656
Heng DY, Wells JC, Rini BI et al (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur Urol 66:704–710. https://doi.org/10.1016/j.eururo.2014.05.034
doi: 10.1016/j.eururo.2014.05.034
pubmed: 24931622
Huang WC, Levey AS, Serio AM et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7:735–740. https://doi.org/10.1016/S1470-2045(06)70803-8
doi: 10.1016/S1470-2045(06)70803-8
pubmed: 16945768
pmcid: 2239298
Jaimes EA (2020) Renal toxicity of systemic therapy for renal cell carcinoma. Semin Nephrol 40:49–58. https://doi.org/10.1016/j.semnephrol.2019.12.006
doi: 10.1016/j.semnephrol.2019.12.006
pubmed: 32130966
Jeon HG, Jeong IG, Lee JW, Lee SE, Lee E (2009) Prognostic factors for chronic kidney disease after curative surgery in patients with small renal tumors. Urology 74:1064–1068. https://doi.org/10.1016/j.urology.2009.05.090
doi: 10.1016/j.urology.2009.05.090
pubmed: 19758688
Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM (2018) Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol 25:e403–e410. https://doi.org/10.3747/co.25.4047
doi: 10.3747/co.25.4047
pubmed: 30464691
pmcid: 6209550
Kim SH, Lee SE, Hong SK et al (2013) Incidence and risk factors of chronic kidney disease in Korean patients with T1a renal cell carcinoma before and after radical or partial nephrectomy. Jpn J Clin Oncol 43:1243–1248. https://doi.org/10.1093/jjco/hyt149
doi: 10.1093/jjco/hyt149
pubmed: 24198287
Méjean A, Ravaud A, Thezenas S et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379:417–427. https://doi.org/10.1056/NEJMoa1803675
doi: 10.1056/NEJMoa1803675
pubmed: 29860937
Perazella MA, Shirali AC (2018) Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol 29:2039–2052. https://doi.org/10.1681/ASN.2018050488
doi: 10.1681/ASN.2018050488
pubmed: 29959196
pmcid: 6065079
Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127. https://doi.org/10.1056/NEJMoa1816714
doi: 10.1056/NEJMoa1816714
pubmed: 30779529
Stakhovsky E, Vitruk I, Voylenko O et al (2013) Functional renal parenchyma score as an indicator for partial nephrectomy in renal tumors. European Urology Supplements vol 11(4) Eur, Prague, Czech Republic.Urol. –, p, vol E 13
Van Poppel H, Da Pozzo L, Albrecht W et al (2007) A Prospective randomized EORTC Intergroup Phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 51:1606–1615. https://doi.org/10.1016/j.eururo.2006.11.013
doi: 10.1016/j.eururo.2006.11.013
pubmed: 17140723
Voylenko OA, Stakhovsky OE, Vitruk IV et al (2021) Efficacy of neoadjuvant targeted therapy in treatment of patients with localised clear-cell renal cell carcinoma. Adv Urol 2021:6674637. https://doi.org/10.1155/2021/6674637
doi: 10.1155/2021/6674637
pubmed: 34012466
pmcid: 8105117
Wanchoo R, Karam S, Uppal NN et al (2017) Adverse renal effects of immune checkpoint inhibitors: A narrative review. Am J Nephrol 45:160–169. https://doi.org/10.1159/000455014
doi: 10.1159/000455014
pubmed: 28076863
Williams T, Rodriguez R, Murray K, Kovaleski A, Madan R, Van Veldhuizen P (2015) Metastatic papillary renal cell carcinoma regression after cytoreductive nephrectomy. Urology 85:283–287. https://doi.org/10.1016/j.urology.2014.10.005
doi: 10.1016/j.urology.2014.10.005
pubmed: 25623665